Can a vaccine cocktail free HIV patients from daily pills?
NCT ID NCT04357821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether a combination of two experimental vaccines, an immune booster, and two powerful antibodies can help people with HIV control the virus after stopping their daily antiretroviral therapy. Eleven participants will receive the regimen while on ART, then pause their regular medication to see if the virus stays at bay. The goal is to achieve a lasting remission, not a cure, as the virus may still be present but kept under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
combination of DNA vaccine, MVA vaccine, TLR9 agonist (lefitolimod), and broadly neutralizing antibodies (VRC07-523LS and 10-1074)
What this could lead to
If it works, this could point toward a way for people with HIV to stop daily antiretroviral therapy and keep the virus under control for months or longer.
What could go wrong
This is a very small, early-phase study with only 11 participants, so results may not apply widely. The combination is complex and could cause side effects, and there is no guarantee of achieving remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zuckerberg San Francisco General Hospital, University of California San Francisco
San Francisco, California, 94110, United States